Section 4 of 6
Clinical evidence
221 evidence topics · 43 sources
Study summaries
OPERA-01
Objective
Trial objective
“OPERA-01 (NCT06016738) is a phase III study designed to evaluate the safety and efficacy of palazestrant monotherapy compared to SOC ET in patients with ER+, HER2– locally advanced or metastatic breast cancer, regardless of ESR1 mutation status, whose disease advanced following treatment with at least one ET in combination with a CDK4/6i.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Main objectives in the EU trial authorization
Location and study date
Registry dates
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2023-11-16” |
| Primary completion (estimated) | “2026-10-31” |
| Study completion (estimated) | “2028-02-29” |
Registration and start of enrollment
“Clinical Trial Registration: Clinicaltrials.gov NCT06016738. Registered 17 August 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Enrollment began in November 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Enrollment completion and expected top-line results
Study design
Randomized, open-label, two-part design
“The OPERA-01 study is a global phase III randomized, open-label, active-controlled study, consisting of two parts (Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Part 2, participants are randomized at a 1:1 ratio to receive once‑daily oral palazestrant (90 mg QD) or the investigator’s choice of SOC ET.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Part 1 dose selection
“In Part 1, the dose-selection portion of the study, eligible participants were randomized 1:1:1 to receive oral palazestrant at a dose of 90 mg or 120 mg once daily (QD) or investigator’s choice of SOC ET” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Independent Data Monitoring Committee recommended a 90-mg palazestrant QD dose based on the available safety, efficacy, patient-reported outcomes, and pharmacokinetic data from participants treated in Part 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prespecified criteria for selecting the Part 2 dose
Stratified randomization
“Participants (N = 510 overall and 470 in the primary analysis) are randomized to treatment arms using Interactive Response Technology, and randomization is stratified based on 1) the presence of ESR1-mut or absence of detectable ESR1 mutations (ESR1-mut-nd), assessed centrally on circulating tumor DNA (ctDNA) collected during screening period in line with NCCN Guidelines [16]; 2) prior lines of ET for advanced disease (1 vs 2); and 3) presence of visceral disease (yes vs no).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Independent data monitoring committee
Eligibility criteria
Population
“Male and female participants aged 18 years or older are eligible for enrollment in the OPERA-01 study if they have a confirmed diagnosis of inoperable locally advanced or metastatic ER+, HER2– breast cancer that is not amenable to curative treatment. Participants must have progressed following treatment with the combination of ET and a CDK4/6i; one additional line of ET is allowed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key inclusion criteria
Receptor status definitions
“Laboratory-confirmed ER+, HER2– breast cancer (per ASCO-CAP guidelines)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“0 or 1+ by IHC for HER2 membrane protein” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key exclusion criteria
Prior antibody-drug conjugates and washout periods
“Prior chemotherapy (including ADC) in the advanced/metastatic setting” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fulvestrant, <28 days prior” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ET, CDK4/6i, everolimus, tacrolimus, alpelisib, or PARP inhibitors, <14 days prior” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Palazestrant and comparator regimens
“In Part 2, participants receive once-daily palazestrant (90 mg QD) or SOC ET as described in Part 1. Fulvestrant or the AIs letrozole, anastrozole, or exemestane (with gonadal suppression in pre- and perimenopausal women or men) are included as the physician’s choice of SOC ET monotherapy for the control arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment cycles and duration
“All treatments are administered in 28-day cycles and continue until confirmed radiographic disease progression, intolerable toxicity, continuous dose-interruption >28 days, investigator or participant decision, or initiation of a non-protocol anti-cancer therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for the endocrine monotherapy control arm
“The SOC ET in the control arm aligns with the NCCN and ASCO guidelines recommending ET monotherapy as a treatment option to delay chemotherapy, supported by evidence demonstrating sustained endocrine sensitivity and responsiveness of ER+, HER2− breast cancer to fulvestrant, tamoxifen, or non-steroidal AIs ET, even after prior ET failures [16–18,45–51]. As a global study, the SOC control arm has been planned to account for regional variations in standard practices.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using progression-free survival by blinded independent central review as the primary endpoint
Dual primary endpoint
“The dual primary endpoint of the overall study is blinded independent committee review (BICR)-assessed PFS, defined as the time from randomization to the date of the first documented progression or death due to any cause, in participants with ESR1-mut and ESR1-mut-nd tumors, to be assessed separately.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for separate analyses by ESR1 mutation status
“However, recent reports indicate that the clinical benefit in ER+, HER2– ABC may be limited to patients with ESR1-mutated (ESR1-mut) tumors, rather than the entire patient population: trials investigating the efficacy of the PROteolysis Targeting Chimera ER degrader (PROTAC), vepdegestrant, and the SERD, imlunestrant, showed progression-free survival (PFS) benefits specific to patients harboring ESR1 mutations [28,29].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory rationale for progression-free survival
Secondary endpoints
“Key secondary endpoints of overall survival (OS), defined as the time from randomization to the date of death due to any cause regardless of whether the patient withdraws from randomized therapy or receives another subsequent anti-cancer therapy, will be assessed separately in participants with ESR1-mut and ESR1-mut-nd tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BICR-assessed PFS in the ITT population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PROs (assessed using EQ-5D-5 L and EORTC QLQ-C30)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tumor and safety assessments
“Adverse event (AE) severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Tumor response and disease progression are assessed locally and centrally using body imaging by computed tomography (preferred) or magnetic resonance imaging. Baseline tumor imaging is performed during screening, within 28 days of randomization, and radiographic assessments are conducted periodically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment: registry record
| Enrollment type | Participants |
|---|---|
| Estimated | “510” |
Participants randomized in Part 1 and planned for the primary comparison
Planned participants per arm
| Part and arm | Planned participants |
|---|---|
| Total | “n = 510” |
| Part 1, each arm (palazestrant 90 mg, palazestrant 120 mg, standard-of-care endocrine therapy) | “n = 40” |
| Part 2, each arm (palazestrant 90 mg, standard-of-care endocrine therapy) | “n = 195 (total 235)” |
Description of analysis sets
Primary and key secondary analyses
“Blinded independent committee review (BICR)-assessed PFS, locally assessed PFS, and overall survival (OS) will be analyzed separately in participants with ESR1-mut tumors and participants with ESR1-mut-nd tumors by Kaplan–Meier (KM) methods; median and 95% confidence intervals (CIs) will be reported. Significant differences between treatment groups will be analyzed using the stratified log-rank test, stratified by a number of prior lines of ET and presence or absence of visceral metastases. Cox regression models will be used to estimate hazard ratios and 95% CIs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Part 1 dose-selection analysis
“In Part 1 of the study, the selected dose was based on analyses of safety, preliminary efficacy, PK/pharmacodynamic (PD) parameters, and other relevant clinical and laboratory data, and there was no formal statistical comparison.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
No efficacy or safety results from OPERA-01 have been reported; enrollment is complete, and top-line results are anticipated in the first quarter of 2027. The trial is open label, with PFS assessed by blinded independent central review as the dual primary endpoint. The 90 mg Part 2 dose was chosen from Part 1 data with no formal statistical comparison. The control arm is endocrine monotherapy (fulvestrant or an aromatase inhibitor), and fulvestrant was recommended to participants who had not previously received it. Eligibility excludes participants with prior chemotherapy in the advanced or metastatic setting, prior elacestrant, or symptomatic visceral disease, permits at most one additional line of endocrine therapy after the endocrine therapy and CDK4/6 inhibitor combination, and requires the most recent endocrine therapy to have lasted at least 6 months. Participants receive a tablet formulation, whereas the earlier monotherapy data were obtained with capsules. The trial design publication was funded by Olema Oncology, which was involved in the study design.
Fulvestrant recommended only for participants without prior fulvestrant
“Fulvestrant was recommended to patients who have not previously received fulvestrant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The inclusion of AI monotherapy ensures consistency with guideline-supported treatment options across diverse clinical settings [16–18,49].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
OP-1250-001
Objective
Study objectives
“This study (NCT04505826) was an open-label, multicenter, phase 1/2 study designed to identify the maximum tolerated dose (MTD), establish the recommended phase 2 dose (RP2D), and investigate the safety, pharmacokinetics (PK), and antitumor activity of single-agent palazestrant in patients with previously treated ER+/HER2− advanced and metastatic breast cancer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary and secondary objectives
Location and study date
Trial registration and data cutoff of the primary publication
Last participant enrolled
Interim data cutoff: dose escalation and dose expansion
Study design
Dose escalation and dose expansion phases
“Phase 1 of the study comprised a dose-escalation phase (1a) to identify the MTD using a rolling 6 patient dose-escalation design with 7 dose levels. Two doses of palazestrant (60 mg/day and 120 mg/day) were selected for the dose-expansion phase (1b) to further characterize the safety, PK, and preliminary antitumor activity of treatment and to establish the RP2D.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2 cohorts at the recommended phase 2 dose
“Phase 2 further explored the safety and antitumor activity of palazestrant at the RP2D (120 mg/day) in patients with measurable disease (primary cohort), nonmeasurable evaluable disease (exploratory cohort), and central nervous system (CNS) metastases (exploratory cohort).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The data presented here include patients from phase 1a/1b and the measurable disease and nonmeasurable evaluable disease cohorts from phase 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose escalation rules
“Dose escalation cohorts enrolled up to 6 patients at each level; each patient was enrolled in only 1 dose cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the event of 1 of 3 patients experiencing a DLT at a given dose level, a total of 6 patients would be treated at that dose level, and dose escalation would proceed if no more than 1 DLT was observed after 1 cycle of treatment. In the event of 2 or more patients experiencing DLTs at a given dose level, dose escalation stopped, and this dose level was declared the maximally administered dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selection of two doses for dose expansion
“Dose selection was based on the observation of confirmed PRs at both dose levels” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“and PK data indicating that palazestrant steady-state plasma concentrations reached the predicted efficacy threshold based on estradiol-supplemented preclinical models for both doses” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose expansion at two dose levels (dose escalation report)
Eligibility criteria
Disease and prior endocrine therapy (all phases)
“Patients eligible for phase 1a of the study included adult men or women of any menopausal status with inoperable histologically or cytologically confirmed ER+/HER2− advanced or metastatic breast cancer who had received at least 1 prior line of endocrine therapy for advanced or metastatic disease for at least 6 months continuously and had received no more than 2 lines of prior chemotherapy regimens for metastatic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion of primary endocrine resistance
“Patients who had disease progression within the first 2 years from the start of adjuvant endocrine therapy were not eligible, since these patients were considered to have tumors with primary endocrine resistance.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Performance status, disease evaluability, and permitted prior therapies
“Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and had evaluable disease. Measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) was not a requirement for the dose escalation phase. Prior CDK4/6 inhibitors, fulvestrant, alpelisib, everolimus, or poly-adenosine diphosphate ribose polymerase inhibitors were allowed if discontinued at least 2 weeks prior to the first dose of palazestrant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Additional criteria for phase 1b and phase 2
“In phase 1b/2 of the study, eligible patients met the same key inclusion criteria defined in phase 1a and were also required to have measurable disease per RECIST v1.1, unless they were enrolled in the nonmeasurable disease cohort of patients with nonmeasurable but evaluable disease. In addition, patients must have received no more than 1 prior chemotherapy regimen for metastatic disease and have received at least 1 (but no more than 4) prior lines of endocrine therapy for advanced or metastatic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria
“Patients were excluded from all phases of the study if they had impaired cardiac function, cerebral vascular disease, or a recent thromboembolic event, an ongoing serious infection or gastrointestinal disorder that could affect absorption of study treatment, a clinically significant history of liver disease consistent with Child–Pugh class B or C, other comorbidities that could affect the patient’s ability to participate in the study, or any condition requiring medications not permitted during the study (e.g., strong CYP3 A4 inhibitors/inducers).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Palazestrant regimen and dose levels
“All patients received oral palazestrant capsules once daily, continuously in 28-day treatment cycles. In this first-in-human study, patients were required to fast for 2 h prior to and 1 h after each palazestrant dose. The initial dose cohort received a dose of palazestrant at 30 mg/day, followed by dose cohorts of 60, 90, 120, 150, 210, and 300 mg/day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ovarian function suppression and restricted concomitant medications
“Pre- or perimenopausal women were required to use luteinizing hormone–releasing hormone agonists for the duration of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“proton pump inhibitors and most common antiemetic medications were not permitted” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Selection of 120 mg/day as the recommended phase 2 dose
“Greater clinical benefit at palazestrant 120 mg/day (46%) versus 60 mg/day (19%) led to selection of 120 mg/day as RP2D and study expansion dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, because patients stayed on this treatment longer, the CBR was numerically better, and the safety profile was similar to that of the 60 mg dose, this dose was further explored in phase 2 of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anticipated dose range after dose escalation
Study outcomes
Rationale for using dose-limiting toxicity as the primary endpoint
Definition of the maximum tolerated dose and dose-limiting toxicities
“The MTD was defined as the highest feasible dose in phase 1a in which fewer than 33% of patients (of at least 6 treated) experienced a treatment-related DLT during cycle 1. In this study, DLTs included any treatment-related fatal adverse event (AE); grade ≥ 3 nonhematologic toxicity (including nausea, vomiting, diarrhea not resolving within 3 days with optimal treatment, and fatigue lasting > 7 days); grade 3 neutropenia (with fever and/or infection); grade 3 thrombocytopenia (with bleeding); grade ≥ 4 hematologic toxicity; grade ≥ 2 AEs that resulted in treatment discontinuation or interruption for at least a week (during cycle 1) or a delay of cycle 2 for at least a week; and protocol-defined elevations of aspartate aminotransferase (AST) or alanine aminotransferase (ALT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ocular toxicity as a dose-limiting toxicity
Safety and pharmacokinetic assessments
“Safety assessments included the monitoring of AEs, clinical laboratory parameters, electrocardiograms, and vital signs. AE severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The assessment of palazestrant single- and multiple-dose PK parameters included the maximum plasma concentration (Cmax), minimum plasma concentration (Cmin), average plasma concentration (Cavg), area under the concentration–time curve from 0–24 h (AUC0–24), effective half-life (t1/2), and time to maximum plasma concentration (Tmax).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy end points: response, clinical benefit rate, and progression-free survival
“Key efficacy end points included assessment of clinical response according to RECIST v1.1; the clinical benefit rate (CBR), defined as the proportion of patients who achieved a complete response (CR), achieved a partial response (PR), or had stable disease (SD) for at least 24 weeks; and progression-free survival (PFS), defined as the time from the date of the first dose to disease progression or death. Biomarker assessments included changes from baseline in circulating tumor DNA (e.g., ESR1 variants) and tumor tissue biomarkers (ERα and Ki67).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and precision
“A sample size of approximately 30 patients per dose group in the phase 1b dose expansion cohorts was expected to provide an estimated precision of ± 19% for any binary event rate assessment. In phase 2, a sample size of approximately 50 patients treated at the RP2D was expected to provide an estimated precision of ± 15% for binary assessments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants enrolled and analyzed
“This study enrolled 146 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the dose escalation phase of the study, 42 patients were treated with once-daily oral palazestrant at doses ranging from 30 to 300 mg” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Baseline demographics and characteristics for all patients treated at 60 mg/day or 120 mg/day (n = 116; including those from the dose-escalation phase) are presented in Table 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 116 patients treated in the 60-mg and 120-mg dose cohorts, 92 (79.3%) patients with measurable disease were evaluable for tumor response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Analysis populations in the primary publication
“All DLT analyses (phase 1a) were performed in patients enrolled in the study during cycle 1 and who either received 75% of the planned palazestrant doses or experienced a DLT during cycle 1. All PK analyses were performed in patients who received at least 1 dose of palazestrant and had adequate postbaseline PK samples for characterization of PK parameters. All safety analyses were performed and PFS assessed in patients who received at least 1 dose of palazestrant. Clinical response (CR or PR) was assessed in patients who received at least 1 cycle of palazestrant, had measurable disease at baseline, and had at least 1 postbaseline tumor assessment. CBR was assessed in patients who received at least 1 cycle of palazestrant, had at least 1 postbaseline tumor assessment, and started their first dose at least 24 weeks before data cutoff. Patients who discontinued study treatment without radiographic progression within 24 weeks from the first dose were not included in the CBR analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Analysis sets in the statistical analysis plan
Results
Participant disposition
Treatment status and reasons for discontinuation at 60 or 120 mg/day
“Among all patients treated with 60 or 120 mg/day palazestrant, 102/116 (87.9%) had discontinued treatment at the time of data cutoff (July 7, 2023) and 14 (12.1%) were ongoing. Reasons for treatment discontinuation included radiographic disease progression (n = 78 [67.2%]), clinical disease progression (i.e., without disease progression per RECIST v1.1) (n = 11 [9.5%]), AEs (n = 7 [6.0%]), withdrawal of consent (n = 4 [3.4%]), and other reasons (n = 2 [1.7%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Baseline characteristics at 60 and 120 mg/day
Prior treatment at 60 and 120 mg/day
“Patients had a median age of 61 years, the majority had measurable or visceral disease (84.5% and 73.3%, respectively), 74.1% of patients received at least 2 prior lines of systemic therapy in the advanced setting (median 2; range, 1–8), approximately two-thirds (63.8%) received at least 2 prior lines of endocrine therapy in the advanced setting (median 2; range, 1–5), and all but 5 patients (95.7%) received prior CDK4/6 inhibitor therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Response and clinical benefit by dose level
Confirmed response after the data cutoff and tumor shrinkage at 120 mg/day
“One additional patient treated at the RP2D had a cPR after the data cutoff date for a total of 4 confirmed PRs (6.0%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A reduction in tumor size (percentage change less than zero) was experienced by 25/64 (39.1%) patients treated at the R2PD, including 8/64 (12.5%) who experienced a > 30% reduction” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Duration of treatment at 120 mg/day
“Palazestrant treatment led to prolonged disease stabilization, with 32/86 (37.2%) of patients treated at 120 mg/day remaining on treatment for ≥ 6 months and 6 (7.0%) remaining on treatment for ≥ 1 year” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Progression-free survival at 120 mg/day, overall and with ESR1 mutation
“The median PFS for patients receiving 120 mg/day palazestrant was 4.8 months (95% CI, 3.5–7.1), with a 6-month PFS rate of 39%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with cancers with ESR1 mutations treated at the R2PD, the median PFS was 5.6 months (95% CI, 4.8-NE), and the 6-month PFS rate was 47%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical benefit rate at 120 mg by subgroup (conference presentation)
“All patients: 40% (32/81)” (opens the source at this quote in a new tab)
“Prior fulvestrant: 41% (22/54)” (opens the source at this quote in a new tab)
“ESR1 mutation: 52% (17/33)” (opens the source at this quote in a new tab)
“ESR1 wild-type: 32% (12/38)” (opens the source at this quote in a new tab)
“3 cPRs and 2 uPRs† in 66 response-evaluable patients” (opens the source at this quote in a new tab)
Second- or third-line subset at 120 mg (conference presentation)
| Population | Median PFS, months [95% CI] | 6-month PFS | CBR |
|---|---|---|---|
| All participants (n=86) | “4.6 [3.5, 6.5]” | “38%” | “40%” |
| Second or third line with or without chemotherapy (n=49) | “7.2 [3.7, 7.8]” | “54%” | “48%” |
| ESR1 mutation (n=36) | “5.6 [3.7, 7.8]” | “46%” | “52%” |
| ESR1 mutation, second or third line with or without chemotherapy (n=23) | “7.3 [5.0, NA]” | “62%” | “59%” |
Second- or third-line subset at 120 mg by ESR1 status (company announcement)
ESR1 wild-type participants at 120 mg (company announcement)
Second- or third-line subset in the primary publication
“In an analysis of 49 patients who received palazestrant as second- or third-line therapy with or without prior chemotherapy, the median PFS was extended to 7.2 months, with a CBR of 48% overall. Similarly, patients with cancers with ESR1 mutations had an extended PFS of 7.3 months and CBR of 59% in this subanalysis” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical benefit by on-treatment change in ESR1 mutations
“In patients who had been treated with the RP2D of 120 mg/day palazestrant and had ctDNA available for analysis, the CBR was 73% (8/11) in patients who had a reduction in ESR1 mutations and 25% (8/32) in those who did not have a reduction in ESR1 mutations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose escalation efficacy
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Dose escalation: dose-limiting toxicities
“Palazestrant doses of up to 300 mg/day resulted in no DLTs, and the MTD was not reached. The majority of treatment-emergent adverse events (TEAEs) were grade 1 or 2 in severity in all dose-escalation cohorts of palazestrant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events occurring in at least 15% of participants, n (%)
Treatment-emergent adverse events at 120 mg/day
“Most patients (95.3%) who received the RP2D of 120 mg/day experienced ≥ 1 TEAE of any grade, most commonly nausea (62.8%), vomiting (29.1%), and fatigue (25.6%). The majority of TEAEs were grade 1 or 2 in severity. Grade 3 TEAEs were reported in 21 (24.4%) patients, most commonly vomiting (n = 4 [4.7%]), neutropenia, nausea, and fatigue (n = 3 each [3.5%]). Eight (9.3%) patients treated with 120 mg/day palazestrant also experienced grade 4 TEAEs, including neutropenia (n = 6), acute respiratory failure (n = 1), and 1 patient experienced 3 grade 4 events (pulmonary embolism, diverticulitis, and acute left ventricular failure).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-related adverse events at 120 mg/day
“The most common TRAEs of any grade were nausea (54.7%), vomiting (24.4%), fatigue (19.8%), neutropenia (20.9%), and headache (15.1%). Grade 3 treatment-related events occurred in 10 (11.6%) patients. Nausea and neutropenia (n = 3 each [3.5%]) and vomiting and fatigue (n = 2 each [2.3%]) were the most common grade 3 TRAEs. Treatment-related grade 4 neutropenia occurred in 5 (5.8%) patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients treated with the RP2D of palazestrant, the rate of treatment-related diarrhea of any grade was 13%, and there were no grade ≥ 3 events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Discontinuations due to adverse events and management of grade 4 neutropenia
“Seven patients discontinued palazestrant due to AEs, of which 5 were assessed as related to palazestrant: grade 4 febrile neutropenia with no evidence of infection, grade 4 neutropenia, grade 3 nausea, grade 3 international normalized ratio increase, and grade 2 fatigue. Of the 6 patients with grade 4 neutropenia, 3 events resolved with a dose interruption (1 week) followed by a dose reduction (to 60 mg/day in 1 patient and to 90 mg/day in 2 patients); these patients continued treatment with no further neutropenia. In 3 patients, grade 4 neutropenia resolved following discontinuation of palazestrant. Grade 4 neutropenia occurred in 1 patient, concurrent with disease progression, and was assessed as not related to palazestrant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Timing of grade 4 neutropenia and monitoring in ongoing studies
“While grade 4 neutropenia events occurred approximately 6-8 weeks after initiation of palazestrant, these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mechanism underlying neutropenia is unknown, and no corresponding trends were observed in preclinical studies of palazestrant (unpublished data).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All ongoing studies with palazestrant include proactive monitoring of blood counts that is more frequent during first 6–8 weeks after initiation of palazestrant, with the possibility for dose reduction or interruption following the detection of grade 3 or 4 neutropenia.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prior CDK4/6 inhibitor exposure among participants with grade 4 neutropenia
QTcF, bradycardia, and photopsia at 120 mg/day
“There were no clinically significant changes in the QT interval corrected by the Fridericia formula (QTcF) in any patients treated with palazestrant, and no QTcF values exceeded 500 ms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TEAEs of oral SERDs observed in less than 10% of patients treated at the RP2D of palazestrant included bradycardia (9%) and photopsia (5%); all bradycardia and photopsia events were grade 1, and there were no dose modifications, interruptions, or discontinuations due to these events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose escalation: photopsia, bradycardia, and dose reductions
Grade 3 treatment-related events at 60 and 120 mg in the interim analysis
Study limitations
Summary
OP-1250-001 was an open-label phase 1/2 study without a comparator arm, which the authors state limits interpretation of the safety profile and antitumor activity. Efficacy estimates come from dose cohorts of 30 participants at 60 mg/day and 86 at 120 mg/day, and only 6 participants were enrolled at 90 mg/day, during dose escalation. Response and CBR analyses used restricted populations: response required measurable disease and a postbaseline assessment (66 response-evaluable participants at 120 mg/day), and the CBR analysis excluded participants who discontinued without radiographic progression within 24 weeks. Two reports of the 120 mg cohort give different values: the peer-reviewed publication reports a CBR of 45.7% in 70 evaluable participants and a median PFS of 4.8 months, and the 2023 conference presentation reports a CBR of 40% (32/81) and a median PFS of 4.6 months. The study excluded primary endocrine resistance; fasted dosing, the exclusion of proton pump inhibitors and most common antiemetics, and a relatively large capsule may have increased gastrointestinal events. The central nervous system metastases cohort is not included in the publication, and the association between ESR1 mutation reduction and CBR is based on 11 and 32 participants (CBR 73% [8/11] versus 25% [8/32]). All 116 participants treated at 60 or 120 mg/day were women, 33.6% had received prior chemotherapy, and 8.6% had received 5 or more prior lines of therapy in the advanced setting.
Open-label design without a comparator arm
“Limitations of this study, as with most early-phase clinical trials, include its open-label design and lack of a comparator arm that limit the interpretation of the observed safety profile and antitumor activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Population excluded primary endocrine resistance
Study conditions that may have increased gastrointestinal events
“In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cross-trial comparisons and small biomarker subgroups
“While between-study comparisons should always be made with caution because of variations in patient populations, equivalent dosing levels, and study designs” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While the correlation between reductions in ESR1 mutations and CBR is encouraging based on a small number of patients, these findings should be further explored in larger trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Central nervous system cohort not reported
OP-1250-003
Objective
Original objective for the ribociclib and alpelisib groups
Location and study date
Registry dates and planned enrollment
| Item | Value |
|---|---|
| Study start (actual) | “2022-08-31” |
| Primary completion (estimated) | “2027-12-31” |
| Study completion (estimated) | “2028-01-31” |
| Enrollment (estimated) | “190” |
Ribociclib group: most recent data cutoff and presentation
Atirmociclib group initiation and enrollment
Study design
Dose-escalation method
Eligibility criteria
Ribociclib group: key eligibility criteria
Prior therapy limits by treatment group in the current registry record
Alpelisib group and central nervous system criteria
Treatment
Alpelisib, everolimus, and atirmociclib group regimens
Study outcomes
Rationale for using dose-limiting toxicities as the primary endpoint
Ribociclib group: primary and secondary endpoints by study part
Dose-limiting toxicity observation period in the ribociclib group
Statistical analysis description
Number of participants (Planned and analyzed)
Planned ribociclib group size after the 2023 amendment
Ribociclib group: enrolled and analyzed participants, July 2025 data cutoff
Ribociclib group: participants by cohort, July 2025 data cutoff
| Cohort | Participants |
|---|---|
| Dose escalation, palazestrant 30 mg | “30 mg (n=3)” |
| Dose escalation, palazestrant 60 mg | “60 mg (n=3)” |
| Dose escalation, palazestrant 120 mg | “120 mg (n=3)” |
| Dose expansion, palazestrant 90 mg | “90 mg (n=16)” |
| Dose expansion, palazestrant 120 mg | “120 mg (n=53)” |
Ribociclib group: March 2024 interim analysis population
Ribociclib group: September 2024 interim analysis population
Description of analysis sets
Follow-up calculation and pharmacokinetic sampling
Results
Participant disposition
Ribociclib group: treatment status, July 2025 data cutoff
Ribociclib group: discontinuations due to adverse events
Baseline characteristics
Ribociclib group: baseline demographics and disease characteristics, July 2025 data cutoff
| Characteristic | Palazestrant 90 mg (n=16) | Palazestrant 120 mg (n=56) | Total (N=72) |
|---|---|---|---|
| Median age, years (range) | “60 (25-76)” | “61 (28-85)” | “61 (25-85)” |
| Female sex, n (%) | “16 (100%)” | “56 (100%)” | “72 (100%)” |
| Premenopausal, n (%) | “4 (25%)” | “8 (14%)” | “12 (17%)” |
| ECOG performance status 0, n (%) | “10 (63%)” | “34 (61%)” | “44 (61%)” |
| ECOG performance status 1, n (%) | “6 (38%)” | “22 (39%)” | “28 (39%)” |
| Measurable disease at baseline, n (%) | “12 (75%)” | “37 (66%)” | “49 (68%)” |
| Visceral disease, n (%) | “6 (38%)” | “33 (59%)” | “39 (54%)” |
| No prior line of therapy in the advanced setting, n (%) | “10 (63%)” | “14 (25%)” | “24 (33%)” |
| One prior line of therapy in the advanced setting, n (%) | “5 (31%)” | “26 (46%)” | “31 (43%)” |
| Two prior lines of therapy in the advanced setting, n (%) | “1 (6.3%)” | “12 (21%)” | “13 (18%)” |
| Three prior lines of therapy in the advanced setting, n (%) | “0” | “4 (7%)” | “4 (6%)” |
| Prior CDK4/6 inhibitor in the advanced setting, n (%) | “5 (31%)” | “40 (71%)” | “45 (63%)” |
| Prior aromatase inhibitor in the advanced setting, n (%) | “5 (31%)” | “27 (48%)” | “32 (44%)” |
| Prior fulvestrant in the advanced setting, n (%) | “1 (6%)” | “22 (39%)” | “23 (32%)” |
| Prior chemotherapy in the advanced setting, n (%) | “1 (6.3%)” | “10 (18%)” | “11 (15%)” |
| ESR1 mutation at baseline | “1/15 (7%)” | “14/54 (26%)” | “15/69 (22%)” |
Ribociclib group: prior CDK4/6 inhibitor exposure and ESR1 mutation status
Efficacy results
Ribociclib group: progression-free survival in the 120 mg cohort, including participants with prior CDK4/6 inhibitor treatment
Ribociclib group: maturity of progression-free survival in the 120 mg cohort
Ribociclib group: progression-free survival in the 90 mg cohort
Ribociclib group: objective response rate, July 2025 data cutoff
| Population | Objective response rate (n/n) |
|---|---|
| 90 mg cohort (n=12) | “42% (5/12)” |
| 120 mg cohort (n=32) | “31% (10/32)” |
| Prior CDK4/6i, 120 mg cohort (n=23) | “26% (6/23)” |
| All (n=44) | “34% (15/44)” |
Ribociclib group: responses after prior CDK4/6 inhibitor treatment
Ribociclib group: 6-month progression-free survival and clinical benefit rate, September 2024 data cutoff
Ribociclib group: clinical benefit rate after prior CDK4/6 inhibitor treatment, November 2024 data cutoff
Ribociclib group: pharmacokinetic interaction results
Ribociclib group: steady-state ribociclib 600 mg exposure, October 2023 data cutoff
| Parameter | Ribociclib single agent | Ribociclib in combination with palazestrant |
|---|---|---|
| AUC0-24 ([h*ng/mL]/mg), GeoMean (GeoCV); N | “23,800 (66%); 54” | “25,400 (78%); 8” |
| Cmax (ng/mL/mg), GeoMean (GeoCV); N | “1,820 (62%); 57” | “1,860 (66%); 8” |
| Tmax (h), Median (min–max); N | “2.4 (0.68–7.8); 57” | “4.0 (1.0–6.0); 8” |
Ribociclib group: CYP3A4 interaction mechanism
Everolimus and atirmociclib groups: first data scheduled for December 2026
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Ribociclib group: dose-limiting toxicities and overall severity
Ribociclib group: related treatment-emergent adverse events in at least 25% of participants, n (%)
| Event | 120 mg (n=56), all grades | 120 mg, grade 3 | 120 mg, grade 4 | 90 mg (n=16), all grades | 90 mg, grade 3 | 90 mg, grade 4 |
|---|---|---|---|---|---|---|
| Neutropenia (combined term) | “47 (84%)” | “28 (50%)” | “5 (9%)” | “13 (81%)” | “9 (56%)” | “2 (16%)” |
| Nausea | “41 (73%)” | “2 (4%)” | “0” | “11 (69%)” | “1 (6%)” | “0” |
| Fatigue | “30 (54%)” | “3 (5%)” | “0” | “9 (50%)” | “0” | “0” |
| White blood cell decrease | “24 (43%)” | “9 (16%)” | “1 (2%)” | “6 (38%)” | “4 (25%)” | “0” |
| Diarrhea | “24 (43%)” | “2 (4%)” | “0” | “4 (25%)” | “0” | “0” |
| Anemia | “22 (39%)” | “2 (4%)” | “0” | “5 (31%)” | “0” | “0” |
| Vomiting | “21 (38%)” | “1 (2%)” | “0” | “4 (25%)” | “0” | “0” |
| Electrocardiogram QT prolonged | “16 (29%)” | “4 (5%)” | “0” | “4 (25%)” | “1 (6%)” | “0” |
| Lymphocyte decrease | “16 (29%)” | “3 (5%)” | “1 (2%)” | “3 (19%)” | “0” | “0” |
| AST increased | “15 (27%)” | “2 (4%)” | “0” | “3 (19%)” | “0” | “0” |
| Constipation | “15 (27%)” | “0” | “0” | “3 (19%)” | “0” | “0” |
Ribociclib group: dose reductions and grade 5 events
Ribociclib group: reasons for ribociclib dose reduction, March 2024 data cutoff
Ribociclib group: QTcF in the dose-escalation analysis
Study limitations
Summary
OP-1250-003 is an open-label phase 1b, 2-part study in 4 treatment groups, and the 2025 presentation cautions that its comparison aggregates results across independent studies and carries the risks inherent in cross-trial comparisons. The ribociclib group population differs from this indication: 24 of 72 participants (33%) had no prior line of therapy in the advanced setting, and 45 (63%) had received a prior CDK4/6 inhibitor. Cohorts include 16 participants at palazestrant 90 mg and 56 at 120 mg, and response rates are based on 12 and 32 response-evaluable participants, respectively. The presentation describes efficacy as “maturing”: 30 of 72 participants (42%) remained on treatment at the July 8, 2025 cutoff, and median PFS in the 90 mg cohort was not reached at a median follow-up of 10.8 months. Responses were assessed by the investigator, and the analysis presented 72 of 78 enrolled participants. Interim results were reported at successive cutoffs (March 13, 2024; September 25, 2024; and July 8, 2025) with different analysis populations.
Open-label design without a comparator group
OP-1250-002
Objective
Primary objectives by study part
Location and study date
Registry dates and enrollment
| Item | Value |
|---|---|
| Study start (actual) | “2021-12-10” |
| Primary completion (estimated) | “2026-03” |
| Enrollment (actual) | “60” |
Study design
Eligibility criteria
Key eligibility criteria
Treatment
Dose escalation and dose expansion regimens
Study outcomes
Rationale for using dose-limiting toxicities as the primary endpoint
Registry primary outcomes
Statistical analysis description
Number of participants (Planned and analyzed)
Enrolled and planned participants, September 2023 data cutoff
Participants by palazestrant dose, September 2023 data cutoff
| Palazestrant dose | Participants |
|---|---|
| 30 mg | “30 mg (n=3)” |
| 60 mg | “60 mg (n=3)” |
| 90 mg | “90 mg (n=3)” |
| 120 mg | “120 mg (n=37)” |
| Total | “Total (N=46)” |
Earlier interim analysis population
Description of analysis sets
Clinical benefit rate and ESR1 analysis populations
Results
Participant disposition
Treatment status and reasons for discontinuation, September 2023 data cutoff
Baseline characteristics
Baseline demographics and disease characteristics, September 2023 data cutoff
| Characteristic | Total (N=46), n (%) |
|---|---|
| Median age, years (range) | “63.5 (30–77)” |
| Female sex | “45 (98)” |
| Premenopausal | “4 (9)” |
| ECOG performance status 0 | “31 (67)” |
| ECOG performance status 1 | “15 (33)” |
| Measurable disease | “36 (78)” |
| Visceral disease | “20 (44)” |
| One prior line of therapy for advanced disease | “34 (74)” |
| One prior line of endocrine therapy for advanced disease | “40 (87)” |
| Prior CDK4/6 inhibitor for advanced disease | “33 (72)” |
| Prior aromatase inhibitor for advanced disease | “35 (76)” |
| Prior fulvestrant for advanced disease | “5 (11)” |
| Prior chemotherapy for advanced disease | “10 (22)” |
| ESR1 mutation at baseline (ctDNA) | “16/37 (43)” |
Efficacy results
Responses, clinical benefit, and treatment duration, September 2023 data cutoff
Clinical benefit rate without prior CDK4/6 inhibitor treatment
Pharmacokinetic interaction results
Palazestrant steady-state pharmacokinetics with palbociclib 125 mg, March 2023 data cutoff
| Palazestrant dose | Cmin (ng/mL) | Cmax (ng/mL) | Cavg (ng/mL) | Tmax (h) | AUC0–24 (ng*h/mL) |
|---|---|---|---|---|---|
| “30 mg (n=2)” | “61.2 (38%)” | “136 (49%)” | “94.7 (13%)” | “2.0 (2.0–2.0)” | “2270 (13%)” |
| “60 mg (n=3)” | “186 (52%)” | “337 (24%)” | “253 (43%)” | “2.0 (2.0–2.0)” | “6070 (43%)” |
| “90 mg (n=3)” | “199 (55%)” | “549 (63%)” | “341 (49%)” | “2.0 (2.0–4.0)” | “8180 (49%)” |
| “120 mg (n=12)” | “313 (43%)” | “573 (43%)” | “429 (39%)” | “4.0 (2.0–6.0)” | “10300 (39%)” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Dose-limiting toxicities and overall severity
Treatment-emergent adverse events in at least 20% of participants, total population (N=46), n (%)
Dose reductions and discontinuations
Fatal events in the earlier interim analysis
Study limitations
Summary
OP-1250-002 is an open-label phase 1b dose-escalation and dose-expansion study. Eligibility allowed zero or one prior endocrine therapy with or without a CDK4/6 inhibitor for advanced disease, which admits participants outside previously treated disease; 33 of 46 participants (72%) had received a prior CDK4/6 inhibitor. The CBR is based on 26 evaluable participants overall and 10 with ESR1 mutations, and circulating tumor DNA for ESR1 testing was available for 37 participants. The reported results have a data cutoff of September 15, 2023, at which 22 participants (48%) remained on treatment and the data were described as maturing. The registry lists an actual enrollment of 60 participants, whereas the reported analysis includes 46.
OPERA-02
Objective
Location and study date
Registry dates and planned enrollment
| Item | Value |
|---|---|
| Study start (actual) | “2025-11-03” |
| Primary completion (estimated) | “2028-12” |
| Study completion (estimated) | “2032-01” |
Study design
Randomized, double-blind, active-controlled design
Stratification factors and randomization ratio
Eligibility criteria
Key inclusion criteria
Key exclusion criteria
Prior endocrine therapy exclusions in the registry record
Treatment
Investigational and control regimens
Study outcomes
Rationale for using investigator-assessed progression-free survival as the primary endpoint
Primary, key secondary, and other secondary endpoints
| Endpoint role | Endpoint |
|---|---|
| Primary endpoint | “PFS, as assessed by local investigator” |
| Key secondary endpoint | “OS” |
| Other secondary endpoint | “PFS (per BIRC)” |
| Other secondary endpoint | “ORR, CBR, and DOR (per local investigator and BIRC)” |
| Other secondary endpoint | “PFS2” |
| Other secondary endpoint | “Safety and tolerability” |
| Other secondary endpoint | “PK” |
| Other secondary endpoint | “Patient-reported outcomes” |
Registry definition of the primary outcome
Regulatory rationale for progression-free survival
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants per arm
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
No results from OPERA-02 have been reported; primary completion is estimated for December 2028, and top-line data are anticipated in 2028. The trial enrolls participants with no prior systemic therapy for advanced breast cancer and tests palazestrant in combination with ribociclib, so its population and regimen are outside this indication of previously treated disease and palazestrant monotherapy. The primary endpoint is investigator-assessed PFS, with PFS by blinded independent central review as a secondary endpoint. Participants previously treated with fulvestrant, elacestrant, or an investigational endocrine therapy in any setting are excluded.